2,4-dimorpholyl-sym-triazine | 91194-78-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 2,4-dimorpholyl-sym-triazine
• 英文别名: 2,4-di-morpholin-4-yl-[1,3,5]triazine；2,4-Dimorpholino-s-triazin；4-(4-Morpholino-1,3,5-triazin-2-YL)morpholine；4-(4-morpholin-4-yl-1,3,5-triazin-2-yl)morpholine
• CAS: 91194-78-4
• 化学式: C₁₁H₁₇N₅O₂
• mdl: MFCD03034624
• 分子量: 251.288
• InChiKey: HLAMCZOWCWTIBU-UHFFFAOYSA-N

物化性质

• 熔点：
  161-162 °C(Solv: ligroine (8032-32-4))
• 沸点：
  472.4±55.0 °C(Predicted)
• 密度：
  1.283±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  63.6
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-cyano-4,6-dimorpholino-1,3,5-triazine 在 盐酸 作用下， 反应 1.0h， 以40%的产率得到2,4-dimorpholyl-sym-triazine
  参考文献：
  名称：

  三嗪类。7. 1,3,5-三嗪系列单腈的水解和环化

  摘要：

  DOI：

  10.1007/s10593-006-0140-0

文献信息

• Anomalous one-pot transformation of 3-dimethoxymethyl-2-(N-cyanoimino)thiazolidine into 6-unsubstituted 2,4-diamino-s-triazines by the reaction with amines
  作者：Tetsuaki Tanaka、Mayumi Watanabe、Yumi Nakamoto、Kaori Okuno、Kaori Maekawa、Chuzo Iwata

  DOI：10.1039/c39940002301

  日期：——

  3-Dimethoxymethyl-2-(N-cyanoimino)thiazolidine 1e reacts with secondary amines to afford 2,4-diamino-s-triazines 4 unexpectedly, while the triazine 5 bearing different amino groups at 2 and 4 positions is selectively obtained by the reaction with a mixture of two kinds of amines.

  3-二甲氧基甲基-2-(N-氰基亚氨基)噻唑啉 1e 与仲胺反应意外地得到2,4-二氨基-s-三嗪 4，而通过与两种不同胺的混合物反应可以选择性地得到在2位和4位带有不同氨基的三嗪 5。
• IN VITRO PRODUCTION OF FOREGUT STEM CELLS
  申请人：Cambridge Enterprise Limited

  公开号：EP3060652A1

  公开（公告）日：2016-08-31
• TREATMENT AGENTS FOR INHIBITING HIV AND CANCER IN HIV INFECTED PATIENTS
  申请人：Redfield Robert R.

  公开号：US20160339030A1

  公开（公告）日：2016-11-24

  Methods are provided for treating HIV and cancer in a subject in need thereof by administering to the subject therapeutically effective amounts of an mTOR inhibitor. Other methods are provided for treating subjects infected with HIV by administering to the subject therapeutically effective amounts of the mTOR inhibitor INK128, GSK2126458, AZD2014 or Torin-2.
• [EN] COMPOUNDS AND THEIR USE IN THERAPY<br/>[FR] COMPOSÉS ET UTILISATION THÉRAPEUTIQUE DE CEUX-CI
  申请人：STICHTING HET NL KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS

  公开号：WO2014184726A2

  公开（公告）日：2014-11-20

  The present invention pertains generally to the field of therapy and medical treatment, and more specifically to certain compounds of the following formula (for convenience, collectively referred to herein as "short-chain phosphatidylcholine lipids" and "SCPC lipids"), which, inter alia, are useful in methods of improving drug delivery, bioavailability, and efficacy. The present invention also pertains to pharmaceutical formulations, and more specifically to co-formulations of known drugs (e.g., amphiphilic drugs) (e.g., anthracyclines) (e.g., doxorubicin) with these SCPC lipids, and their use, for example, in therapy.
• [EN] IN VITRO PRODUCTION OF FOREGUT STEM CELLS<br/>[FR] PRODUCTION IN VITRO DE CELLULES SOUCHES D'INTESTIN ANTÉRIEUR
  申请人：CAMBRIDGE ENTPR LTD

  公开号：WO2015052143A1

  公开（公告）日：2015-04-16

  This invention relates to the differentiation of pluripotent cells (PSCs) into foregut stem cells (FSCs) using a definitive endoderm induction medium comprising a TGFfi ligand, fibroblast growth factor (FGF), bone morphogenetic protein (BMP) and a PI3K inhibitor to differentiate the pluripotent cells into definitive endoderm cells and a foregut induction medium comprising a TGFβ ligand to differentiate the definitive endoderm cells into foregut stem cells (FSCs). Methods of differentiation, populations of foregut stem cells, culture media and kits are provided.